Compare Illumina, Inc. (ILMN) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Prologis Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Prologis Inc trades at $138.85 (market cap $133.20B). The key difference: Prologis Inc is far larger — about 4.6× Illumina, Inc.'s market cap, and Prologis Inc pays a 3.05% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | PLD | |
|---|---|---|
Market Cap | $28.96B | $133.20B |
Sector | Health | Real Estate |
52-Week High | $205.10 | $149.96 |
52-Week Low | $91.00 | $104.81 |
Enterprise Value | $30.32B | $167.94B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Prologis (PLD) trades at $140.16, up 0.73% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights the acquisition of SEGRO for up to $19.2 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show variability, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.
The outlook is positive due to robust earnings growth, strategic acquisitions, and a 57% analyst buy rating with a $159.22 price target. Risks include high debt levels, with debt-to-asset ratio rising to 37.2 in 2025, and integration challenges from the SEGRO deal. Investors should weigh strong profitability against leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
